CIK 0001785530
- Non-accelerated filer
- Smaller reporting company
- Emerging growth company
Werewolf Therapeutics, Inc.
Sign in to watch- Ticker
- HOWL
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 823523180
- Phone
- +1 617-952-0555
- Business address
- 303 WYMAN STREET, SUITE 300, WALTHAM, MA, 02451
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-05-04 | Longwood Fund III GP, LLC 10% owner | Conversion | +1,071,127 | 1,071,127 | ||
| 2021-05-04 | Longwood Fund III GP, LLC 10% owner | Conversion | +355,955 | 1,427,082 | ||
| 2021-05-04 | Longwood Fund III GP, LLC 10% owner | Purchase | +250,000 | $16.00 | $4.0M | 1,677,082 |
| 2021-05-04 | Longwood Fund III GP, LLC 10% owner | Conversion · Series A Preferred Stock | −9,285,714 | 0 | ||
| 2021-05-04 | Longwood Fund III GP, LLC 10% owner | Conversion · Series B Preferred Stock | −3,085,811 | 0 | ||
| 2021-05-04 | Lazarus Alon Director | Conversion | +1,235,917 | 1,235,917 | ||
| 2021-05-04 | Lazarus Alon Director | Conversion | +410,717 | 1,646,634 | ||
| 2021-05-04 | Lazarus Alon Director | Purchase | +400,000 | $16.00 | $6.4M | 2,046,634 |
| 2021-05-04 | Lazarus Alon Director | Conversion · Series A Preferred Stock | −10,714,284 | 0 | ||
| 2021-05-04 | Lazarus Alon Director | Conversion · Series B Preferred Stock | −3,560,551 | 0 | ||
| 2021-05-04 | UPMC 10% owner | Conversion | +823,945 | 823,945 | ||
| 2021-05-04 | UPMC 10% owner | Conversion | +273,811 | 1,097,756 | ||
| 2021-05-04 | UPMC 10% owner | Conversion · Series A Preferred Stock | −7,142,857 | 0 | ||
| 2021-05-04 | UPMC 10% owner | Conversion · Series B Preferred Stock | −2,373,701 | 0 | ||
| 2021-04-30 | DiRocco Derek Director | Grant or award · Stock Option (right to buy) | +23,200 | 23,200 | ||
| 2021-04-30 | Leonard Reid Chief Operating Officer | Grant or award · Stock Option (right to buy) | +27,311 | 27,311 | ||
| 2021-04-30 | Isaacs Randi Chief Medical Officer | Grant or award · Stock Option (right to buy) | +56,786 | 56,786 | ||
| 2021-04-30 | Trost Timothy W. Chief Financial Officer | Grant or award · Stock Option (right to buy) | +54,756 | 54,756 | ||
| 2021-04-30 | Seidel-Dugan Cynthia Chief Scientific Officer | Grant or award · Stock Option (right to buy) | +57,908 | 57,908 | ||
| 2021-04-30 | Lazarus Alon Director | Grant or award · Stock Option (right to buy) | +23,200 | 23,200 |
Page 16 of 17 · 335 trades